
Opinion|Videos|January 17, 2025
MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas
Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing epcoritamab and glofitamab that may influence therapy selection.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you use comparative data from MAIC analyses to guide treatment decisions between available bispecific therapies?
- What do the results of the MAIC comparing epcoritamab and glofitamab suggest about the relative differences of these agents, and how might these influence therapy selection?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Sexual Dysfunction From Cancer Is Widespread—and Many Don’t Know That Before Treatment, Data Show
3
Enzalutamide Combo Improves OS in Prostate Cancer Without Sacrificing Quality of Life: Stephen Freedland, MD
4
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
5